Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
selinexor + venetoclax
- Development stage
- Phase 3
- Lead developer
- Karyopharm Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy of selinexor (an XPO1 inhibitor) and venetoclax (a BCL2 inhibitor). Selinexor prevents the nuclear export of tumor suppressor proteins by inhibiting exportin-1 (XPO1), causing their accumulation in the nucleus and promoting cancer cell death. Venetoclax selectively binds to BCL2, blocking its antiapoptotic function and promoting apoptosis. The combination has shown synergistic effects in various hematological malignancies, particularly in multiple myeloma with t(11;14) translocation, acute myeloid leukemia, and mantle cell lymphoma.
- Brand names
- Nexpovio
- Other names
- Venetoclax + SelenisolVinaclatSelenisol
02
Targets
XPO1 (Exportin-1)
Beyond the preview
Go deeper on selinexor + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on selinexor + venetoclax.